(Q46798803)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1 reference

Rocío García-Carbonero

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Ramon Colomer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

A Jimeno

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

C Grávalos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

P Escudero

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

I Sevilla

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

M E Vega-Villegas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

V Alonso

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

I Juez

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

H Bovio

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

H Cortés-Funes

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

number of pages

6

1 reference

Clinical and Translational Oncology

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

52-57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12094-008-0153-5

1 January 2020

exact match

0 references

cites work

Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-008-0153-5

Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors

21 January 2018

1 reference

12 December 2020

Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

1 reference

12 December 2020

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

12 December 2020

Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma

1 reference

12 December 2020

Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma

1 reference

12 December 2020

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer

1 reference

12 December 2020

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

12 December 2020

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

1 reference

12 December 2020

Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts

1 reference

12 December 2020

Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy

1 reference

12 December 2020

Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

1 reference

12 December 2020

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

1 reference

12 December 2020

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

1 reference

12 December 2020

ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.

1 reference

12 December 2020

The activity and expression of thymidine phosphorylase in human solid tumours

1 reference

12 December 2020

10.1007/S12094-008-0153-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18208793%20AND%20SRC:MED&resulttype=core&format=json

release_gvjqr4nsszh2ncmic2zqy3iseq

1 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gvjqr4nsszh2ncmic2zqy3iseq

24 November 2022

mapped directly with Wikidata item

1 reference